<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04886739</url>
  </required_header>
  <id_info>
    <org_study_id>CGB-400-002</org_study_id>
    <nct_id>NCT04886739</nct_id>
  </id_info>
  <brief_title>CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea</brief_title>
  <official_title>Safety and Effectiveness of CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea: A Randomized, Double-Blind, Vehicle-Controlled Proof of Concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CAGE Bio Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ethica Clinical Research Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CAGE Bio Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, vehicle-controlled, parallel design study&#xD;
      evaluating the efficacy and safety of CGB-400 Topical Gel for the treatment of inflammatory&#xD;
      lesions of rosacea. The study consists of a 12-week double-blind treatment period with clinic&#xD;
      visits at Baseline (Day 0), and Weeks 2, 4, 8, and 12.&#xD;
&#xD;
      Approximately 80 subjects will be enrolled and randomized at a 1:1 ratio to treatment with&#xD;
      either CGB-400 Topical Gel (40%) BID or Vehicle Gel BID.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory Lesion Count</measure>
    <time_frame>Week 12</time_frame>
    <description>Numerical count of inflammatory lesions (pustules and papules)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator Global Assessment (IGA)</measure>
    <time_frame>Week 12</time_frame>
    <description>0 - Clear; No inflammatory lesions present; at most mild erythema&#xD;
1 - Almost clear; Very mild erythema present. Very few small papules/pustules&#xD;
2 - Mild; Mild erythema. Several small papules/pustules&#xD;
3 - Moderate; Moderate erythema. Several small or large papules/pustules&#xD;
4 - Severe; Severe erythema. Numerous small and/or large papules/pustules</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Lesion Count</measure>
    <time_frame>Weeks 2, 4, and 8</time_frame>
    <description>Numerical count of inflammatory lesions (pustules and papules)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Global Assessment (IGA)</measure>
    <time_frame>Weeks 2, 4, and 8</time_frame>
    <description>0 - Clear; No inflammatory lesions present; at most mild erythema&#xD;
1 - Almost clear; Very mild erythema present. Very few small papules/pustules&#xD;
2 - Mild; Mild erythema. Several small papules/pustules&#xD;
3 - Moderate; Moderate erythema. Several small or large papules/pustules&#xD;
4 - Severe; Severe erythema. Numerous small and/or large papules/pustules</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rosacea Quality of Life (RosaQoL) Questionnaire</measure>
    <time_frame>Week 12</time_frame>
    <description>Patient Reported Outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>CGB-400 Topical Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical administration twice daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical administration twice daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CGB-400</intervention_name>
    <description>Topical gel</description>
    <arm_group_label>CGB-400 Topical Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Gel</intervention_name>
    <description>Topical gel</description>
    <arm_group_label>Vehicle Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Outpatient, male or female of any race, 18 years of age or older. Female subjects of&#xD;
             childbearing potential must have a negative UPT at Baseline and practice a reliable&#xD;
             method of contraception throughout the study.&#xD;
&#xD;
          -  Clinical diagnosis of papulopustular facial rosacea.&#xD;
&#xD;
          -  Investigator Global Assessment (IGA) score of 3 or 4 (i.e., moderate or severe).&#xD;
&#xD;
          -  Facial inflammatory lesion count (i.e., papules and pustules) of ≥15 and ≤50&#xD;
             (excluding lesions involving the eyes and scalp) with ≤2 nodules.&#xD;
&#xD;
          -  Willing to forego any other topical or non-topical treatment, cosmetic, OTC, or&#xD;
             prescription on the study areas during treatment (other than sun protection or the&#xD;
             study specified face wash and moisturizer).&#xD;
&#xD;
          -  Willing to use the provided skincare regimen (e.g., face wash, moisturizer) during the&#xD;
             study.&#xD;
&#xD;
          -  In general good health as determined by medical history and physical examination at&#xD;
             the time of screening (Investigator discretion).&#xD;
&#xD;
          -  Sign the IRB-approved ICF (which includes HIPAA) prior to any study-related procedures&#xD;
             being performed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female subjects that are pregnant, breast-feeding, or of childbearing potential and&#xD;
             not practicing reliable birth control (as specified in Section 5.1).&#xD;
&#xD;
          -  Known hypersensitivity or previous allergic reaction to any constituent of the&#xD;
             Investigational Product (i.e., essential oils, fragrance, choline,&#xD;
             phosphatidylcholine, propylene glycol, limonene, cellulose).&#xD;
&#xD;
          -  Any transient flushing syndrome.&#xD;
&#xD;
          -  Particular forms of rosacea (ocular rosacea, rosacea conglobata, rosacea fulminans,&#xD;
             isolated rhinophyma, granulomatous rosacea, phymatous rosacea, plaque-type rosacea&#xD;
             lesions isolated pustulosis of the chin) or other concomitant facial dermatoses that&#xD;
             are similar to rosacea such as peri-oral dermatitis, demodicidosis, facial keratosis&#xD;
             pilaris, seborrheic dermatitis, acute lupus erythematosus, or actinic telangiectasia.&#xD;
&#xD;
          -  Papulopustular rosacea that had required systemic treatment within the past 12 months.&#xD;
&#xD;
          -  Facial skin conditions that can interfere with reliable rosacea assessments (e.g.,&#xD;
             keloids, hypertrophic scarring, dense telangiectasia, plaque-like facial edema, recent&#xD;
             facial surgery, etc.).&#xD;
&#xD;
          -  Facial dermatoses that may be confounded with papulopustular rosacea (e.g., perioral&#xD;
             dermatitis, facial keratosis pilaris, seborrheic dermatitis, acne fulminans, etc.).&#xD;
&#xD;
          -  History or presence of a skin condition/disease that is located in the treatment&#xD;
             area(s) and might interfere with the diagnosis or evaluation of study parameters&#xD;
             (i.e., atopic dermatitis, psoriasis, significant actinic damage, vitiligo, open&#xD;
             wounds, infection, etc.).&#xD;
&#xD;
          -  Basal cell carcinoma within 6 months of Visit 1.&#xD;
&#xD;
          -  Uncontrolled systemic disease.&#xD;
&#xD;
          -  Foreseen unprotected and intense/excessive UV exposure during the course of the study.&#xD;
&#xD;
          -  Use of prohibited concomitant medications/procedures, as specified below in Table 1,&#xD;
             during the study or within the defined washout periods.&#xD;
&#xD;
          -  Scheduled or planned surgical procedures during the course of the study.&#xD;
&#xD;
          -  Unable or unwilling to comply with any of the study requirements.&#xD;
&#xD;
          -  Medical or psychiatric conditions, or a personal situation, that may increase the risk&#xD;
             associated with study participation or may interfere with interpretation of study&#xD;
             results or subject compliance and, in the opinion of the PI, makes the subject&#xD;
             inappropriate for study entry.&#xD;
&#xD;
          -  Clinically significant alcohol or drug abuse, or history of poor cooperation or&#xD;
             unreliability.&#xD;
&#xD;
          -  Exposure to any other investigational drug/device within 30 days prior to study entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nitin Joshi, PhD</last_name>
    <phone>5012299458</phone>
    <email>njoshi@cagebio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Murray Jensen, MSc</last_name>
    <phone>514-337-0442</phone>
    <phone_ext>208</phone_ext>
    <email>mjensen@ethicaCRO.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cage Bio Investigative Site 1</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 30, 2021</study_first_submitted>
  <study_first_submitted_qc>May 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2021</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

